ABL Diagnostics Targets €12.2M in Revenue by 2026, Invest Securities Raises Its Target
Invest Securities reaffirms its positive outlook on ABL Diagnostics and raises its price target, citing expected growth acceleration from 2026 and margin improvement. The analyst highlights a balanced growth model and structural catalysts enhancing business visibility.
A Growth Trajectory of +76.5% in 2026, Driven by Multiple Engines
Invest Securities emphasizes that ABL Diagnostics has, for the first time, communicated an ambitious annual trajectory for 2026, with expected revenue of €12.2M, an increase of 76.5% compared to 2025. This growth is supported by two pillars: the recurrence of historical activities (HIV genotyping/sequencing and software) and the ramp-up of new activities integrated in 2025, whose contribution is expected to grow by 93%. Within this growth, the analyst details a diversified model. Kits and reagents are expected to accelerate by 83%, driven particularly by HIV (an increase of 132%) and the UltraGene range (353%). Services and distribution should almost double, supported by CDL Pharma and Vela Diagnostics. Software solutions are expected to grow by 14%, with a strong recurring base.
Margins and Structuring Partnerships as Levers of Value Creation
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The analyst identifies several value creation factors. ABL Diagnostics has a proprietary offering covering tests, software, and services, organized in an 'agnostic' approach compatible with major sequencing equipment, reducing adoption frictions. The company is preparing to launch innovative solutions, including HybridChek, expanding its application field. Commercially, Invest Securities highlights the importance of structuring strategic partnerships, including a multi-year contract that could reach about €2.7M. Volume increases and economies of scale are expected to generate significant margin improvement, with expected growth in EBITDA and net income. Despite a deteriorated in vitro diagnostics market, the analyst considers the value proposition competitive enough to support market share growth.
Price Target Adjusted to €8.7, Confirming Upside Potential
Invest Securities raises its price target from €8.4 to €8.7, reflecting sustained upside potential. This increase incorporates the ramp-up of growth engines, the expected improvement in profitability profile, and the increased contribution of strategic partnerships. Invest Securities maintains its 'Buy' rating.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 5,4 millions d'euros
Quarterly revenue: 5,4 millions d'euros
Revenue growth: 90,1 %
EBITDA: 1,3 millions d'euros
EBITDA margin: 24,3 %
Net income: 1,3 millions d'euros
Guidance from the release
The achievement of this objective remains dependent on: the timing of orders and deliveries; the ramp-up of the UltraGene range; the development of HIV activities; the contribution of Vela Diagnostics and CDL Pharma; supply conditions; regulatory deadlines
Risks mentioned
Timing of orders and deliveries remains uncertain and critical to achieving 2026 targets
Ramp-up execution of UltraGene range and HIV activities could face delays or operational challenges
Integration of Texcell France operations needs to successfully combine cultures and operations while maintaining financial discipline
Opportunities identified
Ramp-up of the UltraGene range (formerly Fast Track Diagnostics) with €1.582 million target for 2026
Expansion of HIV activities with €3.906 million annual target
Integration of Texcell France assets acquired in July 2026, adding 29 new employees and new virology and biosafety testing services
Outlook / guidance
Expected revenue: 12,3 millions d'euros
Management commentary: On June 1, 2026, ABL Diagnostics published a roadmap targeting annual revenue of €12.265 million in 2026, compared to €6.950 million in 2025, i.e. a targeted annual growth of 76.5%.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
